Towards Healthcare
Biologics Safety Testing Market Size Reaches USD 4.58 Billion in 2025

Biologics Safety Testing Market Fueled by Monoclonal Antibodies and Personalized Medicine Demand in 2025

Market insights predict, the biologics safety testing industry is expected to grow from USD 4.03 billion in 2024 to USD 14.45 billion by 2034, driven by a CAGR of 13.64%. The growing demand for biologics and growing research and development activities drive the market. North America dominated the global market owing to the presence of key players and increasing R&D investments.

Content

  • Insight Code: 5843
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The biologics safety testing market is projected to reach USD 14.45 billion by 2034, growing at a CAGR of 13.64% from 2025 to 2034.

North America is leading the biologics safety testing market due to the availability of state-of-the-art research and development facilities, the presence of key players, and increasing R&D investments.

The biologics safety testing market includes six segments including by product type, by test type, by application, by end-user, by technology, and by region.

Some key players include Sartorius AG, Thermo Fisher Scientific, Lonza Group AG, and Eurofins Scientific.

Key trends include the growing demand for biologics, the rising prevalence of genetic disorders, and stringent regulatory policies.

Licensing a biologic is a determination that the product, the manufacturing process, and the manufacturing facilities meet applicable requirements to ensure continued safety, purity, and potency of the product.

A major side effect of biologics is serious infection, allergic reactions, CNS disorders, cardiac issues, and Lupus-like syndrome.

Clinicaltrials.gov, Food and Drug Administration, Government of Canada, Germany Trade & Invest
Any Questions